(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.02%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.54%.
Kazia Therapeutics's earnings in 2026 is -$16,170,694.On average, 5 Wall Street analysts forecast KZIA's earnings for 2026 to be -$6,243,864,101, with the lowest KZIA earnings forecast at -$9,109,602,744, and the highest KZIA earnings forecast at -$59,513,955. On average, 5 Wall Street analysts forecast KZIA's earnings for 2027 to be -$5,877,711,576, with the lowest KZIA earnings forecast at -$9,498,427,251, and the highest KZIA earnings forecast at $0.
In 2028, KZIA is forecast to generate -$6,590,745,439 in earnings, with the lowest earnings forecast at -$11,998,013,370 and the highest earnings forecast at $0.